Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VIRO.CO
- Price
- 12.05
- Stock movement down
- -0.05 (-0.41%)
- Company name
- ViroGates A/S
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Medical Devices
- Market cap
- 93.20M
- Ent value
- 94.54M
- Price/Sales
- 9.88
- Price/Book
- 19.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -21.44%
- 1 year return
- 24.23%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-12
DIVIDENDS
VIRO.CO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.88 |
| Price to Book | 19.56 |
| EV to Sales | 10.02 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 7.73M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 11.88M |
| Net receivables | 1.65M |
| Total current assets | 17.80M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 17.98M |
| Accounts payable | 1.70M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 9.29M |
| Total liabilities | 13.22M |
| Shareholder's equity | 4.76M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.10 |
| Daily high | 12.10 |
| Daily low | 12.05 |
| Daily Volume | 2K |
| All-time high | 238.00 |
| 1y analyst estimate | - |
| Beta | 0.96 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| VIRO.CO | S&P500 | |
| Current price drop from All-time high | -94.94% | -0.64% |
| Highest price drop | -97.73% | -19.00% |
| Date of highest drop | 10 Oct 2024 | 8 Apr 2025 |
| Avg drop from high | -95.69% | -2.72% |
| Avg time to new high | - | 5 days |
| Max time to new high | 273 days | 89 days |
COMPANY DETAILS
Marketcap
93.20M
Marketcap category
Small-cap
Description
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company's product includes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; and suPARnostic Quick Triage kit for use in the point of care situation for early warning and patient triaging that allows clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression, and outcome. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.
Employees
10
Website
Investor relations
-
SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Institutional Investor Converts Warrants, Injecting $595,000 to Accelerate Nextech3D.ai's Blockchain Ticketing Rollout and Event Token Ecosystem NEW YORK CITY, NY AND TORONTO, ON / ACCESS Newswire / O...
October 7, 2025
All-cash purchase price of approximately $700,000; Eventdex serves 60+ customers; generated ~$750K in 2024 revenue and ~$500K year-to-date 2025. Combination unifies Map D's floor mapping with Eventdex...
September 30, 2025
New high-margin, pure profit revenue stream for Nextech3D.ai. NEW YORK, NY AND TORONTO, ON / ACCESS Newswire / September 3, 2025 / Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a leading provider of ...
September 3, 2025
It's the ultimate convergence of AI, AR, mobile, and crypto - built for the future of live experiences NEW YORK, NY AND TORONTO, ON / ACCESS Newswire / July 24, 2025 /Nextech3D.ai (OTCQB:NEXCF)(CSE:NT...
July 24, 2025
Collaboration Leverages AI to Deliver Cost-Effective, Scalable 3D Product Visualization TORONTO, ON / ACCESS Newswire / March 6, 2025 / Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a leader in AI-po...
March 6, 2025
TORONTO, ON / ACCESS Newswire / January 17, 2025 / Nextech3D.AI (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), established in 2018, has been a pioneer in augmented reality (AR) and artificial intelligence (AI) tec...
January 17, 2025
Nextech3D.AI(OTCQB:NEXCF)(CSE:NTAR)(FSE:EP2), a leading Generative AI-powered 3D model content provider for major e-commerce brands, is pleased to announce its spin-out Toggle.ai (OTCQB:TGGLF)(CSE:TGG...
November 21, 2024